23 assets in Head And Neck Neoplasm

Therapeutic assets addressing Head And Neck Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Head And Neck Neoplasm	Rutgers, The State University of New Jersey	P4	BB (65)
Cyclophosphamide Head And Neck Neoplasm	M.D. Anderson Cancer Center	P3	BB (64)
Pembrolizumab Head And Neck Neoplasm	Mayo Clinic	P3	BB (64)
Capecitabine Head And Neck Neoplasm	Rutgers, The State University of New Jersey	P4	B (62)
Cis-Diamminedichloroplatinum Ii Head And Neck Neoplasm	Hoffmann-La Roche	P3	B (60)
Atezolizumab Head And Neck Neoplasm	University Medical Center Groningen	P2	B (58)
Nivolumab Head And Neck Neoplasm	Fred Hutchinson Cancer Center	P2	B (57)
Disitamab Vedotin Head And Neck Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Entrectinib Head And Neck Neoplasm	Hoffmann-La Roche	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Head And Neck Neoplasm	Haihua Yuan	P2	CCC (53)
Tiragolumab Head And Neck Neoplasm	University Medical Center Groningen	P2	CCC (53)
Zanidatamab Head And Neck Neoplasm	Haihua Yuan	P2	CCC (53)
Sargramostim Head And Neck Neoplasm	Mayo Clinic	P1/2	CCC (48)
Fludarabine Head And Neck Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (45)
htl0039732 capsules Head And Neck Neoplasm	Cancer Research UK	P1/2	CC (45)
Ksq-001Ex Head And Neck Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (45)
n17350 Head And Neck Neoplasm	Onchilles Pharma Inc	P1/2	CC (45)
gh21 Head And Neck Neoplasm	Suzhou Genhouse Bio Co., Ltd.	P1	CC (43)
azd9592 Head And Neck Neoplasm	AstraZeneca	P1	CC (41)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer Head And Neck Neoplasm	Bicara Therapeutics	P1	CC (41)
Osimertinib Head And Neck Neoplasm	AstraZeneca	P1	CC (41)
Diclofenac Head And Neck Neoplasm	The Second Affiliated Hospital of Hainan Medical University	N/A	D (30)
Epi-326 Head And Neck Neoplasm	EpiBiologics	P1	NR ()